MIR367

Summary

MIR367 (microRNA 367, HGNC:31781) is a microRNA gene on chromosome 4q25.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 442912 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:31781
Approved symbol	MIR367
Name	microRNA 367
Location	4q25
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-367
Ensembl gene	ENSG00000199169
Ensembl biotype	miRNA
OMIM	614600
Entrez	442912
RNAcentral	URS0000718CB7 — miRNA, 68 nt, 9 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000362299

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000362299 — 1 exons

Exon	Start	End
ENSE00001437062	112647874	112647941

Expression profiles

Bgee: expression breadth broad, 85 present calls, max score 83.81.

Top tissues by expression

85 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
placenta	UBERON:0001987	83.81	gold quality
adrenal tissue	UBERON:0018303	79.25	gold quality
bone marrow	UBERON:0002371	78.75	gold quality
blood	UBERON:0000178	78.56	gold quality
endometrium	UBERON:0001295	74.85	gold quality
muscle of leg	UBERON:0001383	74.61	gold quality
body of pancreas	UBERON:0001150	74.35	gold quality
gastrocnemius	UBERON:0001388	73.61	gold quality
heart	UBERON:0000948	72.04	gold quality
heart left ventricle	UBERON:0002084	71.21	gold quality
monocyte	CL:0000576	70.66	gold quality
rectum	UBERON:0001052	70.14	gold quality
stomach	UBERON:0000945	69.88	gold quality
right adrenal gland cortex	UBERON:0035827	69.61	gold quality
lung	UBERON:0002048	69.28	gold quality
left adrenal gland	UBERON:0001234	69.16	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	68.96	gold quality
left adrenal gland cortex	UBERON:0035825	68.90	gold quality
right atrium auricular region	UBERON:0006631	68.81	gold quality
right adrenal gland	UBERON:0001233	68.69	gold quality
lower esophagus	UBERON:0013473	68.00	gold quality
lower esophagus muscularis layer	UBERON:0035833	68.00	gold quality
kidney	UBERON:0002113	67.85	gold quality
right frontal lobe	UBERON:0002810	67.85	gold quality
fundus of stomach	UBERON:0001160	67.79	gold quality
urinary bladder	UBERON:0001255	67.79	gold quality
Ammon’s horn	UBERON:0001954	67.74	gold quality
adult mammalian kidney	UBERON:0000082	67.55	gold quality
right lobe of liver	UBERON:0001114	67.54	gold quality
body of uterus	UBERON:0009853	67.38	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.39

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• Stable miR-302-367 cluster expression results in inhibition of CXCR4 leading to the disruption of the sonic hedgehog (SHH)-GLI-NANOG network. (PMID:21720384)
• A putative binding site for microRNA-367 exists in the 3’UTR of RYR3, and a genetic variant, rs1044129 A–>G, is present in this binding region. (PMID:21810988)
• miR-145 and miR-367 may have roles in relapse in surgically treated nonsmall cell lung cancer (PMID:22835608)
• A new cell cycle regulatory pathway was identified ain which the miR-302-367 cluster directly down-regulated both cyclin D1 and AKT1 and indirectly up-regulated p27Kip1 and p21Cip1, leading to the suppression of cervical cancer cell proliferation. (PMID:23185040)
• The current study suggests that the functional variant (rs1044129) in the miR-367 binding site of RYR3 may be a potential marker for prognosis in patients following curative surgery for colorectal cancer (PMID:23393343)
• Targeted serum miRNA (TSmiR) test for diagnosis and follow-up of (testicular) germ cell cancer patients: a proof of principle. (PMID:24012110)
• Overexpression of miR-367 in the paclitaxel-sensitive cells further increased paclitaxel sensitivity, whereas miR-367 depletion decreased paclitaxel sensitivity. (PMID:24220856)
• we demonstrate knockdown of the miR-302/367 cluster by using the Kruppel-associated box repressor domain fused with specific transcription activator-like effectors (TALEs) designed to bind the miR-302/367 cluster promoter. (PMID:24319658)
• findings suggest a novel molecular mechanism for NaB in promoting somatic cell reprogramming via the miR-302/367 cluster. (PMID:24568633)
• miR-367 was reduced in gastric cancer tissues vs paraneoplastic tissues. It correlated with the differentiation level, TNM stage, and metastasis of gastric cancer. Rab23 was a target gene of miR-367. (PMID:25489984)
• MicroRNA-302/367 cluster governs hESC self-renewal by dually regulating cell cycle and apoptosis pathways (PMID:25801506)
• Study identified miR-367 as a negative regulator of Smad7 expression in pancreatic cancer cells by directly targeting its 3’-UTR. (PMID:25867271)
• The pro-oncogenic activity of miR-367 in medulloblastoma. (PMID:26250335)
• Combination of high-miR-196a and low-miR-367 expression may be a novel biomarker in identifying a poor prognosis group of high-grade glioma. (PMID:26261539)
• Clustering expression levels of miR-302 validated target genes showed a significant correlation between miR-302/367 cluster miRNAs and a subset of validated gene targets in healthy and adjacent tumor tissues. (PMID:26363379)
• A serum/CSF miRNA panel (miR-371a-3p, miR-372-3p, miR-373-3p and miR-367-3p) was sensitive and specific for diagnosing pediatric extracranial malignant GCT as well as detecting relapse, and distinguishing GCT vs. non-GCT intracranial neoplasms. (PMID:26671749)
• MiR-367 was aberrantly upregulated in sera and tumors of esophageal squamous cell carcinoma (ESCC) patients, whereas downregulated in ESCC patients after the treatments of esophagectomy and chemotherapy. (PMID:26777997)
• MiR-367 promotes the proliferation and invasion of non-small cell lung cancer via targeting FBXW7. (PMID:28000899)
• High miR367 expression is associated with non-small cell lung cancer. (PMID:28656290)
• FBXW7 was a downstream target of miR-367 and CASC2 prohibited epithelial-to-mesenchymal transition progression and subsequently exerted its anti-metastatic effects via CASC2/miR-367/FBXW7 axis in hepatocellular carcinoma cells. (PMID:28716020)
• Mir-367 regulates PTEN expression and promotes uveal melanoma cell migration and cell proliferation in vitro. (PMID:28829890)
• The oncogenic roles of miR-367 exerting on the self-renewal ability of cancer stem-like cells through degrading the suppressive FBXW7, eventually helping to maintain Wnt signaling activation through a LIN28B/Let-7 dependent manner. (PMID:28949784)
• Long non-coding RNA XIST (lncRNA XIST) and zinc finger E-box binding homeobox 2 (ZEB2) were targets of miR-367 and miR-141. (PMID:29339211)
• this study demonstrated that miR-302a-5p/367-3p mediated the ability of HMGA2 to regulate the malignant behaviour of endometrial carcinoma cells. (PMID:29391048)
• PIWIL3 was also a target of CEBPA, forming a positive feedback loop in the growth regulation of glioma cells. Significantly, knockdown of OIP5-AS1 combined with over-expression of PIWIL3 and miR-367-3p resulted in tumor regression and extended survival in vivo. (PMID:29464001)
• CD69 is a direct target of miR-367-3p. (PMID:30015935)
• Our findings demonstrate that circYAP1 functions as a tumor suppressor in GC cells by targeting the miR-367-5p/p27 (Kip1) axis and may provide a prognostic indicator of survival in GC patients. (PMID:30336780)
• Results indicated that Linc00961 could directly sponge miR367 at special recognition sites in skin melanoma (SM) cells. (PMID:31364744)
• findings reveal possible clinical applications of a cancer stemness pathway, highlighting miR-367 as a putative liquid biopsy biomarker that could be further explored to improve early diagnosis and prognosis prediction, and potentially serve as a therapeutic target in aggressive embryonal CNS tumors. (PMID:31402560)
• miR-371a-3p, miR-373-3p and miR-367-3p: high miR levels at start of chemotherapy of Metastatic Testicular Germ Cell Cancers are associated with worse clinical outcome and can assist in early diagnosing of relapses. (PMID:31597402)
• TTN-AS1 promoted colorectal cancer proliferation and invasion through miR-376a-3p/KLF15 axis. Our findings suggested that TTN-AS1 might be a potential therapeutic target in CRC treatment. (PMID:31610194)
• Downregulation of linc00961 contributes to promote proliferation and inhibit apoptosis of vascular smooth muscle cell by sponging miR-367 in patients with coronary heart disease. (PMID:31646586)
• MicroRNA-367-3p overexpression represses the proliferation and invasion of cervical cancer cells through downregulation of SPAG5-mediated Wnt/beta-catenin signalling. (PMID:31792998)
• his review provides a critical overview of miR-302/367 cluster dysregulation and the subsequent effects in cancer and highlights the vast potential of members of this cluster as therapeutic targets and novel biomarkers. (PMID:31957939)
• Long non-coding RNA OIP5-AS1 promotes the growth of gastric cancer through the miR-367-3p/HMGA2 axis. (PMID:31959478)
• miR-16 enhances miR-302/367-induced reprogramming and tumor suppression in breast cancer cells. (PMID:32057163)
• MiR-367 alleviates inflammatory injury of microglia by promoting M2 polarization via targeting CEBPA. (PMID:33150481)
• miR3673p downregulates Rab23 expression and inhibits Hedgehog signaling resulting in the inhibition of the proliferation, migration, and invasion of prostate cancer cells. (PMID:34278506)
• Up-Regulated LncRNA FEZF1-AS1 Promotes the Progression of Cervical Carcinoma Cells via MiR-367-3p/SLC12A5 Signal Axis. (PMID:34362591)
• [miR-367-3p Regulates Cells Proliferation and Invasion in NSCLC by Targeting ZEB2]. (PMID:36419391)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.